|
Post by brentie on Apr 16, 2015 8:43:45 GMT -5
I'm not going to the Annual Shareholders Meeting but I was wondering if Mechstan is and if so will you be recording it again? mnkd.proboards.com/post/4789
|
|
|
Post by nemzter on Apr 18, 2015 8:41:48 GMT -5
Here's Matt's email: mpfeffer@mannkindcorp.com Being "in the business", I just don't see spirometry as a high hurdle. It can either be done in the physician's office (for which he/she can bill insurance), at a local hospital, or at a free-standing facility. It would be useful to see if they are hearing any feedback on this requirement. We all know how Matt can be out of tune at times. This is just another example of Management's lack of insight (sorry, OPC rant here lol) I have a friend who runs medical clinics out in the west coast (with 5000 diabetic patients). This is the biggest hurdle they are going through since Sanofi requires that the spirometry test be done from his conversations with them. He will be buying 5 of these for his clinics so he can get his patients tested and be able to have his doctors prescribe on the spot.
|
|
|
Post by cretin11 on Apr 18, 2015 23:05:47 GMT -5
Here's Matt's email: mpfeffer@mannkindcorp.com Being "in the business", I just don't see spirometry as a high hurdle. It can either be done in the physician's office (for which he/she can bill insurance), at a local hospital, or at a free-standing facility. It would be useful to see if they are hearing any feedback on this requirement. We all know how Matt can be out of tune at times. This is just another example of Management's lack of insight (sorry, OPC rant here lol) I have a friend who runs medical clinics out in the west coast (with 5000 diabetic patients). This is the biggest hurdle they are going through since Sanofi requires that the spirometry test be done from his conversations with them. He will be buying 5 of these for his clinics so he can get his patients tested and be able to have his doctors prescribe on the spot. Nemzter, how many of those 5000 patients does your friend expect to get prescribed Afrezza?
|
|
|
Post by gomnkd on Apr 19, 2015 12:41:56 GMT -5
It is not being out of tune. It is doing the job. Why would management say "we are facing significant issues in getting docs to prescribe the drug, or 2nd appointment with endo takes 5 months...".
Top mgmt of all firms are exceptionally good in smooth sales talk and are eternal optimists. Their actions generally speak louder than their words. You go figure.
You always come out very impressed and satisfied after meeting these people. The issue with going to these meetings is that you meet more kool-aid drinkers, grow even more attached to the company, fail to be critical when things go wrong and lose objectivity.
|
|
|
Post by pktrump on Apr 19, 2015 20:30:02 GMT -5
There is no doubt there is a real need to educate Endocrinologists on the pharmokinetics, benefits, dosing, etc.. of AFZ, and that SNY is in part responsible for this task. However, there is also a responsibility on part of Endocrinologists to learn and understand this drug given its inherent kinetics, benefits, and the widespread diabetes epidemic that is upon us; my opinion is that the most of the initiative to understand AFZ lies with Endocrinologists, not SNY.
If an Endo I visited did not know of AFZ at this point I would find another, or a generalist that does. Endos should be far better than us shareholders at understanding AFZ at this point without a SNY rep stopping by. Also, given the sheer number of DM in this country alone, I think FPs, General Practitioners, and PAs will be of more importance in both educating and prescribing in the long term. Thankfully, AFZ is relatively easy to use/dose and understand compared to RAAs.
|
|
|
Post by seanismorris on Apr 19, 2015 20:43:40 GMT -5
Personally, Al impresses me...but the rest of the management team not so much.
I'm confident Mannkind can produce as much Afrezza as there is demand for, but they'd be incompetent not to be able to at this point (they've had plenty of time to plan for it given the delays getting Afrezza approved).
I don't want to hear another report that everything is proceeding as expected; essentially kicking the can down the road to the next meeting.
Afrezza is Sanofi's responsibility, and mostly out of Mannkinds control. If they spend to much time on it (plus the financials) Mannkind and my investment is a waste of time.
Afrezza is Mannkinds Cash Flow, but not the companies' future. Technosphere is the companies future, and I want to hear about how they are agressively pursuing those opportunities.
My concern is the company's urgency or lack thereof. Maybe Al's money (providing job security) is making them lazy. Perhaps it's time to remove that support (or appear to) and throw these people into the fire.
|
|
|
Post by mrhaigs on Apr 19, 2015 21:25:29 GMT -5
Someone needs to man up and have some balls at this meeting. I wish I could go to be that guy but I canf. I feel like these are nothing but appeasements and almost scripted and Very fakely run events. Someone needs to hit them with the hard questions. Ask why their product isn't being sold as expected yet. Ask why sanofi hasn't started the "hard launch" yet. If they try to say that's all up to sanofi, that's total horseshit. It's the only thing he company has right now, has spent over 3 billion getting it to this point and if they think they can tel shareholders it's all Sanofi then they are fools. Of course they know the answers to all of these questions and they need to be held accountable. Ask why no one has bought shares on the open market at these so called depressed values. Ask why certain individuals have been selling at these depressed prices? And a pre planned sale is not an acceptable answer as they can be cancelled without a pending news event and guess what. There haven't been any. The product obviously works as we can see from early adopters but enough is enough with these horrendous script counts for the past few weeks. They need to be put on the spot and the person doing so can't back down.
|
|
|
Post by mnkdorbust on Apr 19, 2015 23:43:38 GMT -5
I'd love to hear Al speak at it personally. He seems to be out of the picture to an extent at this point but also appeared to be muzzled during the last calls where he was present. He's a straight shooter and these other guys are slick.
I would also agree with seanismorris that on the outside it looks like these guys are all over compensated. At this point we have to have faith that SNY knows what they hell they are doing here. I suspect (and hope) they do and they better as their future in the Diabetes market relies on it. The silence is brutal. I personally expected validation that the new lines were approved and firing on all cylinders by now. The success of Afrezza has millions/billions impact on competitors and is a huge threat. Due to this i would think there would be a lot of cards held tight to the vest which is why i hope this is why we are essentially in the dark.
I won't be able to attend the meeting but did add to my position on Friday.
|
|
|
Post by cusop on Apr 20, 2015 6:15:35 GMT -5
Reverse SPLIT never helps a retail share holder its the death nell ..
|
|
|
Post by orlon on Apr 20, 2015 10:51:32 GMT -5
Proxy question number two: Compensation....I voted No! Whatever happened to performance based compensation. This group of management have done absolutely nothing to enhance shareholder value, nor have had a strong enough voice (read balls) to push Sanofi on its AFREZZA launch, never mind the secret plan that some board members speak of, on a product that could be helping millions today. I remember Al Mann dressing down the previous FDA CHIEF on a panel discussion about the time and cost to bring a new drug to market (10 years/1billion dollars) while a whole generation is denied the benefit of a faster approval process. Now that AFREZZA is approved and on the market, little has been done to get the drug/device into the hands of people who could benefit. It's time to shake up the company. No more excuses or BS, no more slow rollout BS...if the product is good, push it, if not pull it. In any event, let's stop pretending the company has no say in how Sanofi markets AFREZZA, it's Mannkind's product. By Jove...I'm beginning to sound like OPC!
|
|
|
Post by suebeeee1 on Apr 20, 2015 20:23:50 GMT -5
We should all talk about how we should vote and vote in a block if possible. Of course, if we don't vote the way Al does, our votes won't matter as he still holds most of the cards and then the "over compensated executives" hold stock options for most of the rest.
|
|
|
Post by dreamboatcruise on Apr 22, 2015 2:16:14 GMT -5
We should all talk about how we should vote and vote in a block if possible. Of course, if we don't vote the way Al does, our votes won't matter as he still holds most of the cards and then the "over compensated executives" hold stock options for most of the rest. Not that it makes much difference, but speaking from personal experience, employee options don't come with votes.
|
|
|
Post by babaoriley on Apr 24, 2015 17:41:18 GMT -5
For those of you who go, you ought to find out where you can pick up pitchforks and torches on the way from NY to Danbury. In case you're wondering, yes, you'll be able to write off the costs of those items!
|
|
|
Post by liane on Apr 24, 2015 18:40:25 GMT -5
For those of you who go, you ought to find out where you can pick up pitchforks and torches on the way from NY to Danbury. In case you're wondering, yes, you'll be able to write off the costs of those items! Only if you are the leader of a stockholders revolt.
|
|
|
Post by ezmit on Apr 27, 2015 13:56:28 GMT -5
If share price continues to decline the shareholders meeting could get interesting.
|
|